Robert Glynn, PhD, ScD

Harvard Medical School, Brigham and Women's Hospital
Boston, MA, United States

Amgen (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)AstraZeneca (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Kowa (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Novartis (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Pfizer (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM – 6:20 PM CEST

• Emulating Stratified Randomized Trials by Propensity Score Methods

  Saturday, August 27, 2022
  9:15 AM – 9:30 AM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM – 9:45 AM CEST

• Concurrent Use of Prescription Opioids with Other Medications and Risk of Fall and Fracture in Rheumatoid Arthritis Patients

  Sunday, August 28, 2022
  1:30 PM – 1:45 PM CEST